Treatment

Genetics, Medical/Science, Recurrence, Treatment

Ibrance-Faslodex Combo Continues To Improve Overall Survival in Advanced-Stage, Hormone-Receptor-Positive Breast Cancer

The targeted therapy Ibrance (chemical name: palbociclib) combined with the hormonal therapy Faslodex (chemical name: fulvestrant) continued to offer better overall survival than Faslodex alone for advanced-stage, hormone-receptor-positive, HER2-negative breast cancer after more than 6 years of follow-up, according to the latest results from the PALOMA-3 trial.

Scroll to Top